Acesso livre
Acesso livre

Infectologia

Debate: os comprovantes de vacinação são uma alternativa válida ao lockdown?

5 Nov, 2021 | 17:15h

Are vaccine passports and covid passes a valid alternative to lockdown? – The BMJ

Comunicado de imprensa: Covid passes: the best way of preventing another lockdown or a threat to civil freedoms and rights? – BMJ

Reino Unido aprova a pílula antiviral da Merck para COVID-19.

5 Nov, 2021 | 17:14h

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first – NPR

Conteúdos relacionados:

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

OMS aprova o uso emergencial da vacina indiana Covaxin.

4 Nov, 2021 | 12:09h

WHO issues emergency use listing for eighth COVID-19 vaccine – World Health Organization

Comentários:

WHO Gives India’s Covaxin Approval, Opening the Door to COVAX distribution – Health Policy Watch

WHO green-lights India’s COVID vaccine as global cases rise – CIDRAP

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo observacional mostrou que a vacina de dose única da J&J teve efetividade de 74% contra Covid-19 sintomática.

4 Nov, 2021 | 12:07h

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19 – JAMA Network Open

Comentários:

Single-Dose Ad26.COV2.S Vaccine—Room for Improvement – JAMA Network Open

Real-world study shows J&J COVID-19 vaccine 74% effective – CIDRAP

Conteúdos relacionados:

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

CDC Report: Moderna’s vaccine associated with greater effectiveness (93%) against Covid-19 hospitalization compared to Pfizer (88%) and J&J (71%) vaccines.

[Preprint] Observational study finds single-dose Johnson & Johnson vaccine is 76.7% effective in preventing SARS-CoV-2 infection

RCT: Single-Dose Johnson & Johnson Vaccine has 85% efficacy against severe/critical Covid-19 and maintains efficacy against variant B.1.351

Diretriz do CDC | Pessoas imunocomprometidas podem precisar de uma quarta dose de vacina contra Covid-19.

4 Nov, 2021 | 12:05h

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Comentários:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

Diretriz ASH emite recomendação condicional contra o uso rotineiro de anticoagulação profilática ambulatorial em pacientes com COVID-19 depois da alta hospitalar.

4 Nov, 2021 | 12:03h

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis – Blood Advances

Dez coisas a saber sobre a síndrome inflamatória multissistêmica em crianças (multisystem inflammatory syndrome in children – MIS-C).

4 Nov, 2021 | 12:01h

Ten Things to Know About MIS-C – American College of Cardiology

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Programa nacional de vacinação contra HPV na Inglaterra foi associado com uma redução estimada de 87% nas taxas de câncer do colo do útero naquelas que receberam a vacina entre 12-13 anos de idade.

4 Nov, 2021 | 11:59h

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Conteúdos relacionados:

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Comentário no Twitter

 

M-A | Zinco pode ajudar a cessar os sintomas de infecção respiratória e encurtar a duração da doença – “Contudo, a qualidade da evidência é variável, e não há clareza sobre uma formulação ou uma dose ótimas.”

4 Nov, 2021 | 11:54h

Comunicado de imprensa: Zinc might help to stave off respiratory infection symptoms and cut illness duration – BMJ

Estudo original: Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials – BMJ Open

 

Comentário no Twitter

 

Conselho do CDC endossa a vacina da Pfizer contra Covid-19 para crianças de 5 a 11 anos.

3 Nov, 2021 | 11:18h

Slides da apresentação do ACIP: November 2-3, 2021 Meeting – Centers for Disease Control and Prevention

Comentários:

CDC advisors give go-ahead to COVID-19 vaccines for young kids – CIDRAP

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11 – STAT

American Academy of Pediatrics Applauds CDC Advisory Committee’s Approval of Safe, Effective COVID-19 Vaccine for Children Ages 5-11

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.